
    
      To evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy of GR1405
      injection monotherapy in an open, non-controlled, escalating trial design in patients with
      advanced solid tumors or lymphomas. Four dose levels (3 mg/kg, 10 mg/kg, 20 mg/kg, and 30
      mg/kg) were evaluated at this stage.
    
  